New gene therapy shows 73% success rate for blood cancer

economictimes.indiatimes.com

A new gene therapy for blood cancer, called CAR T-cell therapy, has shown a 73% response rate in clinical trials in India. This treatment modifies patients' T-cells to fight specific blood cancers like leukemia and lymphoma. Developed by researchers from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, the therapy is now approved in India and costs about $30,000. This is significantly lower than similar therapies in developed countries, which can exceed $373,000. The trials involved 64 patients with relapsed or refractory B-cell malignancies. While the therapy showed promising results, there were some treatment-related deaths and common side effects included low blood cell counts.


With a significance score of 5.6, this news ranks in the top 1% of today's 17344 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 9000 minimalists.


loading...

Timeline:

    [4.7]
    CAR T-cell therapy shows 73% response rate in India (thehindu.com)
    9h
    Source